|1.||Denny, William A: 4 articles (07/2013 - 09/2004)|
|2.||Ware, David C: 4 articles (07/2013 - 09/2004)|
|3.||Brothers, Penelope J: 3 articles (07/2013 - 12/2010)|
|4.||Wilson, William R: 3 articles (07/2013 - 09/2004)|
|5.||Chang, John Yu-Chih: 3 articles (07/2013 - 12/2010)|
|6.||Stevenson, Ralph J: 3 articles (07/2013 - 12/2010)|
|7.||Lu, Guo-Liang: 3 articles (07/2013 - 12/2010)|
|8.||Tercel, Moana: 2 articles (07/2013 - 08/2011)|
|9.||Clark, George R: 2 articles (07/2013 - 12/2010)|
|10.||Suh, Junghun: 2 articles (07/2010 - 01/2009)|
06/24/2014 - "Here we report that active K-Ras4B, which is prominently found to be mutated in human tumors, exhibits a dynamic equilibrium like H-Ras, which can be modulated by Zn2+-cyclen. "
12/01/2007 - "We labeled 1C1, a humanized monoclonal antibody against both human and murine EphA2, with (64)Cu through the chelating agent 1,4,7,10-tetraazacyclododecane N,N',N'',N'''-tetraacetic acid (DOTA) and carried out positron emission tomography (PET) imaging of eight tumor models with different EphA2 expression levels. "
12/21/2011 - "PET imaging using the (18)F labeled zinc-cyclen complex revealed significantly higher uptake in an irradiated Dunning R3327-AT1 prostate tumor as compared to the contralateral control tumor. "
01/01/2011 - "Cyclen-based cationic lipids for highly efficient gene delivery towards tumor cells."
07/01/2007 - "Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer."
11/04/2004 - "Reversible redox behavior and stability of the cyclen-Cu(II) complex in aqueous solution correlated with good hypoxia selectivity. "
11/04/2004 - "The cyclen mustard complex showed 24-fold selectivity as a hypoxia-selective bioreductive prodrug, with an IC50 value of 2 microM against the lung tumor cell line A549. "
12/28/2010 - "Syntheses of 8-quinolinolatocobalt(III) complexes containing cyclen based auxiliary ligands as models for hypoxia-activated prodrugs."
08/15/2011 - "N-alkylated cyclen cobalt(III) complexes of 1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-5-ol DNA alkylating agent as hypoxia-activated prodrugs."
07/01/2013 - "Cross-bridged cyclen or cyclam Co(III) complexes containing cytotoxic ligands as hypoxia-activated prodrugs."
|3.||Parkinson Disease (Parkinson's Disease)
12/21/2011 - "Zn(II)-bis(cyclen) complexes and the imaging of apoptosis/necrosis."
12/21/2011 - "In the ongoing search for an alternative imaging agent, we synthesized a series of fluorescent zinc-cyclen complexes as annexin A5 mimics and studied structural variations on the uptake behavior of cells undergoing apoptosis/necrosis. "
|5.||Type 2 Diabetes Mellitus (MODY)
|5.||Proteins (Proteins, Gene)
|10.||Sodium Channels (Sodium Channel)